{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:11:51Z","timestamp":1777497111340,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012633","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000}}],"reference-count":311,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012633.pub2","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T21:49:52Z","timestamp":1655761792000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Anne","family":"Adams","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Scheckel","sequence":"additional","affiliation":[{"name":"Institute of Health Economics and Clinical Epidemiology; University of Cologne, Faculty of Medicine and University Hospital Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anissa","family":"Habsaoui","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Haque","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Kuhr","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bohlius","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine; University of Bern; Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"10.1002\/14651858.CD012633.pub2-BIB0001|cit1","unstructured":"Aapro M Barnadas A Leonard RC Marangolo M Untch M Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of the BRAVE trial Breast Cancer Research and Treatment 2006 Abstract 6095"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2007.11.5378","article-title":"Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and\/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) Study","volume":"26","author":"Aapro","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0003|cit3","unstructured":"Leonard RC Aapro M Chan S Dirix LY Mayordomo J Reichert D Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy Annals of Oncology 2004 iii.50 (Abstract 188p)"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Abels R Erythropoietin for anemia in cancer patients European Journal of Cancer 1993 2 8","DOI":"10.1016\/S0959-8049(05)80281-3"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Abels R Recombinant human erythropoietin in the treatment of the anaemia of cancer Acta Haematologica 1992 4 11","DOI":"10.1159\/000204780"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the treatment of the anemia of cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0007|cit7","unstructured":"Ansari NN Abbasi B Fardad F Mehrara M Ramim T Comparing the effectiveness of ferric carboxymaltose and oral iron in treatment of chronic iron deficiencyanemia in colon cancer patients Supportive Care in Cancer 2016 S37-S38"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0008|cit8","first-page":"127","article-title":"Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: a single-centre randomised study","volume":"8","author":"Aravantinos","year":"2003","journal-title":"Journal of Balkan Union of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0009|cit9","first-page":"9-15","article-title":"Recombinant human erythropoietin in children with solid tumors and chemotherapy-induced anemia","volume":"10","author":"Ataollah Hiradfar","year":"2018","journal-title":"Iranian Journal of Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2013.09.028","article-title":"Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy","volume":"131","author":"Athibovonsuk","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ajh.21779","article-title":"Darbepoetin alfa 300 or 500 \u03bcg once every 3 weeks with or without intravenous Iron in patients with chemotherapy-induced anemia","volume":"85","author":"Auerbach","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"26","author":"Bastit","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/phar.1729","article-title":"A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUNDTrial","volume":"36","author":"Birgegard","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"28","key":"10.1002\/14651858.CD012633.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2010.30.4899","article-title":"Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study","volume":"29","author":"Blohmer","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0016|cit16","unstructured":"Blohmer JU Wuerschmidt J Petry K Weise G Sehouli J Kimming R Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer: results of a prospective, randomized, open and controlled AGO and NOGGO-intergroup study Annals of Oncology. Vol. 15 Suppl 3 2004"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.bjc.6600801","article-title":"Impact of epoetin beta on quality of life in patients with malignant disease","volume":"88","author":"Boogaerts","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0018|cit18","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004 RO 205-3859"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","article-title":"Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo","volume":"12","author":"Cascinu","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the treatment of the anemia of cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jnci\/85.10.801","article-title":"Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy","volume":"85","author":"Case","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0023|cit23","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004 RO 205-3859"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1200\/JCO.2004.12.027","article-title":"Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"23","author":"Chang","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3816\/SCT.2004.n.023","article-title":"Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy","volume":"2","author":"Chang","year":"2004","journal-title":"Supportive Cancer Therapy"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Charu V Belani CP Gill AN Bhatt M Ben-Jacob A Tomita D A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer Annual Meeting Proceedings of the American Society of Clinical Oncology 2004 abstract 8084","DOI":"10.1200\/jco.2004.22.14_suppl.8084"},{"issue":"6","key":"10.1002\/14651858.CD012633.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1634\/theoncologist.12-6-727","article-title":"Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial","volume":"12","author":"Charu","year":"2007","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Charu V Saidman B Ben-Jacob A Justice GR Maniam AS Rearden T Improvements in fatigue are associated with early treatment with darbepoetin alfa every 3 weeks in anemic patients receiving chemotherapy Journal of Supportive Oncology 2005 14 5","DOI":"10.1182\/blood.V104.11.233.233"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0029|cit29","first-page":"693","article-title":"Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy","volume":"29","author":"Christodoulou","year":"2009","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0030|cit30","unstructured":"Janinis J Dafni U Aravantinos G Kalofonos HP Papakostas P Tsavdaridis D Quality of life (QoL) outcome of epoietin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by the Hellenic Cooperative Oncology Group Proceedings of the American Society of Clinical Oncology 2003 789"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammacco","year":"1998","journal-title":"International Journal of Clinical and Laboratory Research"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.radonc.2014.06.005","article-title":"Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa","volume":"112","author":"Debus","year":"2014","journal-title":"Radiotherapy and Oncology"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.1997.15.7.2715","article-title":"Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia","volume":"15","author":"Del Mastro","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1362::AID-CNCR36>3.0.CO;2-T","article-title":"Erythropoietin reduces anemia and transfusions","volume":"86","author":"Dunphy","year":"1999","journal-title":"Cancer"},{"issue":"13","key":"10.1002\/14651858.CD012633.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1200\/JCO.2009.25.1835","article-title":"Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial","volume":"28","author":"Engert","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0038|cit38","unstructured":"Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/bjc.2011.395","article-title":"Randomised, phase III trial of epoetin-B to treat chemotherapy-induced anaemia according to the EU regulation","volume":"105","author":"Fujisaka","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"S8","key":"10.1002\/14651858.CD012633.pub2-BIB0040|cit40","first-page":"viii385","article-title":"A phase III, randomized, double-blind placebo-controlled study of epoetin beta in lung and gynecological cancer receiving platinum-based chemotherapy: Japan Erythropoietin Study Group","volume":"21","author":"Yoshizaki","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Gage J Gascan P Nagarkar R Smakal M Syrigos K Barrios C Long-term safety and efficacy of darbepoetin alfa in subjects with advanced stage NSCLC receiving multi-cycle chemotherapy Journal of Thoracic Oncology 2017 S1091-S1092","DOI":"10.1016\/j.jtho.2016.11.1526"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Gascon P Nagarkar R Smakal M Syrigos K Barrios CH Cardenas Sanchez J Long-term safety and efficacy of darbepoetin alfa in subjects with stage IV NSCLC receiving multi-cycle chemotherapy Annals of Oncology 2017 iii48","DOI":"10.1093\/annonc\/mdx091.056"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtho.2019.10.005","article-title":"A randomized, double-blind, placebo-controlled, phase III noninferiority study of the long-term safety and efficacy of darbepoetin alfa for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer","volume":"15","author":"Gascon","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Henry D Hirsh V Kubota K Steinmetz T Thomas G Kang JH Randomized, double-blind, placebo (P)-controlled phase III noninferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: an ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) < 10.0 g\/dL Annals of Oncology 2018 viii499-viii500","DOI":"10.1093\/annonc\/mdy292.010"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Nagarkar R Gascon P Smakal M Syrigos K Barrios C Cardenas Sanchez J A double-blind, randomized, placebo-controlled phase 3 noninferiority study of darbepoetin alfa for anemia in advanced NSCLC Journal of Thoracic Oncology 2018 S359","DOI":"10.1016\/j.jtho.2018.08.325"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Gilreath JA Makharadze T Boccia RV Krupa A Henry DH Efficacy and safety of ferric carboxymaltose injection in reducing anemia in patients receiving chemotherapy for non-myeloid malignancies: a phase 3, placebo-controlled study (Iron Clad) Blood 2019","DOI":"10.1182\/blood-2019-132135"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3109\/10428194.2015.1079314","article-title":"Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group","volume":"57","author":"Goede","year":"2016","journal-title":"Leukaemia & Lymphoma"},{"issue":"6","key":"10.1002\/14651858.CD012633.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1634\/theoncologist.2007-0241","article-title":"Treating anemia of cancer with every-4-week darbepoetin alfa: Final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study","volume":"13","author":"Gordon","year":"2008","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Gordon DH Nichols G Ben-Jacob A Lam H Lillie T Miller C Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-Blind, placebo-controlled study in cancer patients not receiving chemotherapy and\/or radiotherapy Blood 2006 abstract 1304","DOI":"10.1182\/blood.V108.11.1304.1304"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Goss G Feld R Bezjak A Perry G Melosky B Smith C Impact of maintaining Hb with epoetin alfa on time to progression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients Lung Cancer 2005 S53","DOI":"10.1016\/S0169-5002(05)80288-0"},{"issue":"36","key":"10.1002\/14651858.CD012633.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1200\/JCO.2005.01.8507","article-title":"Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Grote","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0052|cit52","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit(epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0053|cit53","first-page":"13","article-title":"Recombinant human erythropoietin in patients of advanced Cancer treated \"by chemoradiotherapy\"","volume":"8","author":"Gupta","year":"2009","journal-title":"Landes Bioscience"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.34172\/ipp.2021.32","article-title":"Treatment of chemotherapy induced anemia; a randomized clinical trial to compare quality of life in patients taking intravenous versus oral iron","volume":"7","author":"Hajigholami","year":"2021","journal-title":"Immunopathologia Persa"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0055|cit55","unstructured":"Aranesp\u00ae (darbepoetin alfa) safety Oncologic Drugs Advisory Committee, 4 May 2004"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","article-title":"Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study","volume":"122","author":"Hedenus","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0057|cit57","unstructured":"Hedenus M Brandberg Y Molostova V Iosova G Abdulkadyrov K Messinger D Efficacy of epoetin beta in treating the anaemia of cancer in patients with haematological malignancies Proceedings of the 6th Congress of the European Haematology Association 2001 abstract 190"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies, a rndomized multicenter study","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12032-014-0302-3","article-title":"Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy","volume":"31","author":"Hedenus","year":"2014","journal-title":"Medical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiotherapy and Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0062|cit62","first-page":"292","article-title":"Erythropoietin in patients with head and neck carcinomas?","volume":"83","author":"Schipper","year":"2004","journal-title":"Laryngorhinootologie"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1634\/theoncologist.1-3-140","article-title":"Recombinant Human Erythropoietin (rHuEPO) for the treatment of the anemia of cancer","volume":"1","author":"Abels","year":"1996","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0064|cit64","unstructured":"Henry DH Abels RI Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies Seminars in Oncology 1994 21 8"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0065|cit65","first-page":"252","article-title":"Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy","volume":"1","author":"Henry","year":"1995","journal-title":"Cancer Journal from Scientific American"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Henry DH Dahl NV Auerbach M Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis? Blood 2007 abstract 1625","DOI":"10.1182\/blood.V110.11.1625.1625"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1185\/03007990903084164","article-title":"Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia","volume":"25","author":"Hernandez","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Taylor K Ganly P Charu V DiBenedetto J Kracht K Rossi G Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia Blood 2005 abstract 3556","DOI":"10.1182\/blood.V106.11.3556.3556"},{"issue":"34","key":"10.1002\/14651858.CD012633.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1200\/JCO.2009.22.3693","article-title":"Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in paatients receiving radical radiotherapy with curative intent for head and neck cancer","volume":"27","author":"Hoskin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0071|cit71","unstructured":"Johnson & JPR & D Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0072|cit72","unstructured":"Huddart RA Welch RS Chan S Perren T Atkinson R A prospective randomised comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy Annals of Oncology 2002 177 388"},{"issue":"6","key":"10.1002\/14651858.CD012633.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0885-3924(03)00070-8","article-title":"Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial","volume":"25","author":"Iconomou","year":"2003","journal-title":"Journal of Pain & Symptom Management"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Ferrini","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0075|cit75","unstructured":"Kotasek D Albertsson M Mackey J Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors Proceedings of the American Society of Clinical Oncology 2002 21 356a"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0076|cit76","unstructured":"Kotasek D Albertsson M Mackey J Steger G Rossi G O'Byne J Once per cycle dosing of darbepoetin alfa is feasible in anemic cancer patients receiving chemotherapy Annals of Oncology 2002 170"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0077|cit77","unstructured":"Kotasek D Berg R Poulsen E Colowick A Randomized, double-blind, placebo controlled, phase I\/II dose finding study of ARANESP (TM) administered once every three weeks in solid tumor patients Blood 2000 abstract 1268"},{"issue":"14","key":"10.1002\/14651858.CD012633.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0959-8049(03)00456-8","article-title":"Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study","volume":"39","author":"Kotasek","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.clon.2008.06.001","article-title":"Epoetin delta: efficacy in the treatment of anaemia in cancer patients receiving chemotherapy","volume":"20","author":"Krzakowski","year":"2008","journal-title":"Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/gyno.1997.4675","article-title":"Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study","volume":"65","author":"Kurz","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"25","key":"10.1002\/14651858.CD012633.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(03)01163-X","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","author":"Leyland-Jones","year":"2003","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0083|cit83","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Aapro MS Cella D Zagari M Age, anemia, and fatigue Seminars in Oncology 2002 55 9","DOI":"10.1016\/S0093-7754(02)70175-9"},{"issue":"8","key":"10.1002\/14651858.CD012633.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1023\/A:1026116426494","article-title":"Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients","volume":"12","author":"Fairclough","year":"2003","journal-title":"Quality of Life Research"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD012633.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012633.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(02)00827-6","article-title":"Erythropoietin improves quality of life","volume":"3","author":"Littlewood","year":"2002","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpainsymman.2005.08.013","article-title":"Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies","volume":"31","author":"Littlewood","year":"2006","journal-title":"Journal of Pain & Symptom Management"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hon.722","article-title":"Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy","volume":"21","author":"Littlewood","year":"2003","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000061296","article-title":"Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy","volume":"37","author":"Littlewood","year":"2002","journal-title":"Frontiers of Radiation Therapy and Oncology"},{"issue":"16","key":"10.1002\/14651858.CD012633.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200321160-00002","article-title":"Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer","volume":"21","author":"Martin","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2010-0020","article-title":"Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-\u03b2 for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study","volume":"15","author":"Maccio","year":"2010","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0094|cit94","unstructured":"Johnson & JPR & D Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0095|cit95","unstructured":"Luksenburg H Weir A Wager R Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy FDA Briefing Document May 4, 2004 Oncologic Drugs Advisory Committee"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Machtay M Pajak T Suntharalingam M Hershock D Stripp DC Cmelak A Definitive radiotherpay +\/- erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03 International Journal of Radiation Oncology, Biology, Physics 2004 S132","DOI":"10.1016\/j.ijrobp.2004.06.031"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2007.04.063","article-title":"Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)","volume":"69","author":"Machtay","year":"2007","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijrobp.2014.12.018","article-title":"Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck","volume":"91","author":"Shenouda","year":"2015","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0099|cit99","first-page":"49","article-title":"Effects of epoetin alfa on anemia and patient-reported outcomes in patients with non-small cell lung cancer receiving chemotherapy: results of a European, multicenter, randomized, controlled study","volume":"3","author":"Milroy","year":"2011","journal-title":"European Journal of Clinical and Medical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0100|cit100","unstructured":"Moebus V Bastert G Kreienberg R Eidtmann H Cierna M Untch M Epoetin alpha prevents anemia and transfusions of rbcs in patients (pts) receiving dose-dense sequential chemotherapy [abstract] Proceedings of the American Society of Clinical Oncology 2001 10a, Abstract 36"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jnci\/djt145","article-title":"Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial","volume":"105","author":"Moebus","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Moebus V Lueck H Thomssen C Harbeck N Nitz U Kreienberg R The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) Journal of Clinical Oncology 2007 569","DOI":"10.1200\/jco.2007.25.18_suppl.569"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Moebus V Untch M du Bois A Lueck H J Thomssen C Kuhn W Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (>= 4 +LN). First results of an AGO-trial Journal of Clinical Oncology 2004 abstract 513","DOI":"10.1200\/jco.2004.22.14_suppl.513"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Untch M Jackisch C Lenhard MS du Bois A Lueck HJ Thomssen C Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) Journal of Clinical Oncology 2005 613","DOI":"10.1200\/jco.2005.23.16_suppl.613"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0105|cit105","first-page":"3495","article-title":"Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment","volume":"25","author":"Mystakidou","year":"2005","journal-title":"Anticancer Research"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1106-17","DOI":"10.1080\/01635581.2018.1504090","article-title":"Feasibility of intravenous iron isomaltoside to improve anemia and quality of life during palliative chemotherapy for esophagogastric adenocarcinoma","volume":"70","author":"Ng","year":"2018","journal-title":"Nutrition and Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0107|cit107","doi-asserted-by":"crossref","unstructured":"Ng O Keeler B Simpson JA Madhusudan S Brookes MJ Acheson AG Iron isomaltoside to improve oesophagogastric adenocarcinoma related anaemia and quality of life during chemotherapy Gut 2018 A177-A178","DOI":"10.1136\/gutjnl-2018-BSGAbstracts.353"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mdt505","article-title":"Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer","volume":"25","author":"Nitz","year":"2014","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"e129-e137","DOI":"10.1111\/ajco.12762","article-title":"Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents","volume":"14","author":"Noronha","year":"2018","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Noronha V Patil VM Joshi A More S Goud S Punatar S Phase III open label randomized controlled trial comparing intravenous iron sucrose to oral ferrous sulphate (without erythropoiesis stimulating agents) in the treatment of cancer related iron deficiency anemia Journal of Clinical Oncology 2016","DOI":"10.1200\/JCO.2016.34.15_suppl.10136"},{"issue":"6","key":"10.1002\/14651858.CD012633.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3816\/CBC.2005.n.002","article-title":"Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy","volume":"5","author":"O'Shaughnessy","year":"2005","journal-title":"Clinical Breast Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0112|cit112","doi-asserted-by":"crossref","unstructured":"O'Shaugnessy J Vukelja S Savin M Holmes FA Jones M Royall D Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy: a double-blind, randomized, placebo-controlled trial Proceedings of the American Society of Clinical Oncology 2002 abstract 1449:S116 S120","DOI":"10.3816\/CBC.2002.s.022"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0113|cit113","unstructured":"Ehmer B Schrenk U Franks W Quardor O Messinger D Clinical efficacy of epoetin beta (EPO) in the correction of chemotherapy (CT) induced anemia in patients with solid cancer: a randomized controlled clinical trial Annals of Oncololgy 1996 A2960"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0114|cit114","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004 RO 205-3859"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0115|cit115","unstructured":"Oberhoff C Krumeich B Winkler UH Hoffmann O Schindler AE Recombinant human erythropoietin (epoetin beta) in the treatment of chemotherapy - associated anaemia: effects on blood coagulation and fibrinolysis in patients with gynecological malignancies Annals of Hematology 2000 79 Suppl 3 B16"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1008296622469","article-title":"Recombinant human erythropoietin in the treatment of chemotherapy- induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study","volume":"9","author":"Oberhoff","year":"1998","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1055\/s-2005-858478","article-title":"Prevention and therapy of anemia in tumor patients with Epoetin beta (NeoRecormon)","volume":"26","author":"Oberhoff","year":"2005","journal-title":"Tumor Diagnostik und Therapie"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0118|cit118","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004 RO 205-3859"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0120|cit120","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004 RO 205-3859"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-\u00df on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2005.05440.x","article-title":"Impact of epoetin-\u00df on survival of patients with lymphoproliferative malignanices: long-term follow up of a large randomized study","volume":"129","author":"Osterborg","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3, Art. No.: CD","key":"10.1002\/14651858.CD012633.pub2-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006158.pub2","article-title":"Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer","author":"Lambin","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Overgaard J Hoff C Sand Hansen H Specht L Overgaard M Grau C Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp\u00ae) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial European Journal of Cancer Supplements 2007 abstract 6LB","DOI":"10.1016\/S1359-6349(07)70099-X"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0127|cit127","first-page":"6007","article-title":"Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial","volume":"27","author":"Overgaard","year":"2009","journal-title":"ASCO Meeting Abstracts"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha","volume":"26","author":"Pedrazzoli","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD012633.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2007.15.0748","article-title":"Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide","volume":"26","author":"Pirker","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0130|cit130","unstructured":"Pronzato P Cortesi E Van der Rijt C Moreno-Nogueria A Raimundo D Ostler P Early intervention with epoetin alfa in breast cancer (BC) patients (pts) undergoing chemotherapy (CT): results of a randomized, multicenter, phase IIIb study (EPO-INT-47 Study Group) Annals of Oncology 2002 168"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1634\/theoncologist.2009-0279","article-title":"Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial","volume":"15","author":"Pronzato","year":"2010","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0132|cit132","unstructured":"Quirt I Micucci S Moran LA Pater J Browman G The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled clinical trial Blood 1996 347a"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0133|cit133","doi-asserted-by":"crossref","unstructured":"Ray-Coquard I Dussart S Goillot C Mayeur D Debourdeau P Ghesquieres H A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin {alpha}: a prospective randomized controlled trial of the ELYPSE study group Annals of Oncology 2009 doi:10.1093\/annonc\/mdn750","DOI":"10.1093\/annonc\/mdn750"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0134|cit134","unstructured":"Ray-Coquard I Perol D Debourdeau P Chabaud S Chelghoum M Mayeur D ELYPSE 4: a prospective randomized trial comparing Epo A in primary prophylaxis of severe anemia requiring red cells transfusion in high risk patients Annals of Oncology 2006 ix294"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0136|cit136","unstructured":"Hinds PS Hockenberry M Feusner J Hord JD Rackoff W Rozzouk BI Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy Journal of Supportive Oncology 2005 10 1"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"Razzouk BI Hockenberry M Hinds PS Feusner J Rackoff W Hord JD Influence of hemoglobin response to epoetin alfa on quality-of-life in anemic children with cancer receiving myelosuppressive chemotherapy Blood 2004 abstract 221","DOI":"10.1182\/blood.V104.11.2218.2218"},{"issue":"22","key":"10.1002\/14651858.CD012633.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.2005.03.4371","article-title":"Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy","volume":"24","author":"Razzouk","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0139|cit139","unstructured":"Rose E Rai K Revicki D Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO) Blood 1994 526a"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpainsymman.2003.06.010","article-title":"The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events","volume":"27","author":"Rosenzweig","year":"2004","journal-title":"Journal of Pain & Symptom Management"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/sj.bjc.6600994","article-title":"A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer","volume":"88","author":"Smith","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0142|cit142","unstructured":"Glaspy J Smith RE Aapro M Ludwig H Pinter T Smakal M Results from a phase 3 randomized, double blind, placebo controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy Haematologica 2007 136"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2007.14.2885","article-title":"Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"26","author":"Smith","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","article-title":"Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia","volume":"29","author":"Steensma","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"Strauss H Haendgen G Dunst J Koelbl H Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer Proceedings of the American Society of Clinical Oncology 2003 abstract 5121","DOI":"10.1200\/jco.2005.23.16_suppl.5121"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0146|cit146","doi-asserted-by":"crossref","unstructured":"Strauss HG Haendgen G Dunst J Haywrad CR Burger HU Scherhag A Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer International Journal of Gynecological Cancer 2008 515 24","DOI":"10.1111\/j.1525-1438.2007.01032.x"},{"issue":"11","key":"10.1002\/14651858.CD012633.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/bjc.1998.331","article-title":"Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open- labelled, phase II trial","volume":"77","author":"Sweeney","year":"1998","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/0360-3016(93)90299-B","article-title":"Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial","volume":"26","author":"Vijayakumar","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology and Physics"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0149|cit149","unstructured":"Neorecormon (epoetin beta) Briefing package or the FDA Oncologic Advisory Committee Meeting, May 4, 2004 RO 205-3859"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0150|cit150","doi-asserted-by":"crossref","unstructured":"Reed N Rhan S Hayward C Burger H Ten Bokkel Huinink W Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy Proceedings of the American Society of Clinical Oncology 2003 abstract 5102","DOI":"10.1200\/jco.2005.23.16_suppl.5102"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","article-title":"Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy","volume":"15","author":"Ten Bokkel Huinink","year":"1998","journal-title":"Medical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1200\/JCO.1995.13.7.1623","article-title":"Clinical and and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer","volume":"13","author":"De Campos","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"3-4","key":"10.1002\/14651858.CD012633.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjc.6690369","article-title":"Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer","volume":"80","author":"Thatcher","year":"1999","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD012633.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"918-925","DOI":"10.3324\/haematol.2015.140988","article-title":"A randomized phase II trial of azacitidine +\/- epoetin-\u03b2 in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents","volume":"101","author":"Th\u00e9pot","year":"2016","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0155|cit155","unstructured":"Thomas H McAdam KF Thomas RJ Joffe JK Sugden EM Awwad ST Early intervention with epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy Annals of Oncology 2002 177, #653P"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0156|cit156","unstructured":"Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2007.10.011","article-title":"Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g\/dL with erythropoietin vs above 10.0 g\/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer","volume":"108","author":"Thomas","year":"2008","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0158|cit158","unstructured":"Throuvalas NA Antonadou D Boufi M Lavey R Malamos N Erythropoietin decreases transfusion requirements during radiochemotherapy Proceedings of the American Society of Clinical Oncologists 2000 Abstract 1558"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1753-5174.2010.00030.x","article-title":"Epoetin theat in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial","volume":"3","author":"Tjulandin","year":"2010","journal-title":"Archives of Drug Information"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0160|cit160","unstructured":"Buchner A Bias P Epoetin theta shows efficacy and safety in a placebo controlled, randomized phase III study in cancer patients receiving non-platinum chemotherapy Onkologie 2009 88, Abstract V348"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1753-5174.2011.00035.x","article-title":"Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial","volume":"4","author":"Tjulandin","year":"2011","journal-title":"Archives of Drug Information"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0162|cit162","doi-asserted-by":"crossref","unstructured":"Toma A Chevret S Kosmider O Delaunay J Stamatoullas A Rose C A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO Journal of Clinical Oncology 2013","DOI":"10.1200\/jco.2013.31.15_suppl.7002"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jjco\/hyn151","article-title":"Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study","volume":"39","author":"Tsuboi","year":"2009","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0164|cit164","unstructured":"Watanabe M Ezaki K Tobinai K Tsuboi M Ohashi Y Hirashima K A multicenter phase III randomized, double-blind placebo-controlled study of Epoetin beta administered once-weekly for chemotherapy induced anemia (CIA) in cancer patients: Japan Erythropoietin Study Group Annals of Oncology 2006 294"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdq709","article-title":"PREPARE trial: A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin\/cyclophosphamide followed by paclitaxel (plus or minus) darbepoetin alfa in primary breast cancer-results at the time of surgery","volume":"22","author":"Untch","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Untch M Fascing PA Bauernfeind I Conrad U Camara O Fett W PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin\/cyclophosphamide followed by paclitaxel +\/- darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery Journal of Clinical Oncology 2008 abstract 517","DOI":"10.1200\/jco.2008.26.15_suppl.517"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0167|cit167","unstructured":"Amgen I Aranesp\u00ae (darbepoetin alfa) safety Oncologic Drugs Advisory Committee, 4 May 2004"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0168|cit168","unstructured":"Kallich JD Tchekmedyian NS Damiano AM Shi J Black JT Erder MH Psychological outcomes associated with anemia-related fatigue in cancer patients Oncology (Huntingt) 2002 117 24"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Pirker R Vansteenkiste J Gateley J Yates P Colowick A Musil J A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer Proceedings of the American Society of Clinical Oncology 2001 abstract 1572","DOI":"10.1016\/S0959-8049(01)81473-8"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cncr.11463","article-title":"The relationship between psychologic distress and cancer-related fatigue","volume":"98","author":"Tchekmedyian","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0171|cit171","unstructured":"Tchekmedyian S Glaspy J Colowick A Tomita D Rossi G Effect of darbepoetin alfa and recombinant human erythropoietin (rHuEPO) on early hemoglobin (Hb) changes in anemic cancer patients (pts) Annals of Oncology 2002 13 Suppl 5 184"},{"issue":"16","key":"10.1002\/14651858.CD012633.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","article-title":"Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.[see comment]","volume":"94","author":"Vansteenkiste","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0173|cit173","unstructured":"Vansteenkiste J Poulsen E Rossi G Glaspy J Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations Oncology (Huntingt) 2002 45 55"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00520-003-0583-0","article-title":"Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline","volume":"12","author":"Vansteenkiste","year":"2004","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0175|cit175","doi-asserted-by":"crossref","unstructured":"James RD Wilkinson PM Belli F Welch R Cowan R Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results Acta Haematologica 1992 12 5","DOI":"10.1159\/000204782"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0176|cit176","first-page":"261","article-title":"Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer","volume":"1","author":"Welch","year":"1995","journal-title":"Cancer Journal of the Scientific American"},{"issue":"7","key":"10.1002\/14651858.CD012633.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6603004","article-title":"Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial","volume":"94","author":"Wilkinson","year":"2006","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2008.20.4966","article-title":"Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia","volume":"27","author":"Winquist","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0179|cit179","doi-asserted-by":"crossref","unstructured":"Dicato M Vercammen E Liu KL Xiu LX Bowers P Relationship of body weight to efficacy of a fixed-dose regimen of epoetin alfa vs placebo in anemic cancer patients Haematologica 2005 abstract 0077","DOI":"10.1200\/jco.2005.23.16_suppl.8192"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","article-title":"Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy","volume":"23","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncoogy"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2006.07.1514","article-title":"Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia","volume":"25","author":"Wright","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0182|cit182","first-page":"173-7","article-title":"Clinical observation of recombinant human erythropoietin on chemotherapy-induced anemia in patients with gastrointestinal cancer","volume":"27","author":"Zhao","year":"2018","journal-title":"Chinese Journal of New Drugs"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0183|cit183","doi-asserted-by":"crossref","unstructured":"Antonadou D Cardamakis E Puglisi M Malamos N Throuvalas N Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study European Journal of Cancer 2001 S144","DOI":"10.1016\/S0959-8049(01)81022-4"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000067766","article-title":"Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group","volume":"64","author":"Bamias","year":"2003","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0185|cit185","doi-asserted-by":"crossref","unstructured":"Boccia RV Dahl NV Strauss WE Severe hypophosphatemia in patients with cancer following IV iron treatment: results from a large comparative trial Blood 2019","DOI":"10.1182\/blood-2019-126149"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"848-855","DOI":"10.1002\/cncr.26341","article-title":"Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia\/lymphoma: results of a randomized clinical trial","volume":"118","author":"Cabanillas","year":"2012","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0187|cit187","unstructured":"Carabantes FJ Benavides M Trujillo R Cobo M Hebrero ML Garcia S Epoetin alfa in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy (CT) (CT). A prospective randomized study Proceedings of the American Society of Clinical Oncology 1999 596a. Abstract 2303"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0190|cit190","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0191|cit191","doi-asserted-by":"crossref","unstructured":"Fenaux P Santini V Aloe Spiriti M Giagounidis A Schlag R Radinoff A Challenging IWG2006 response criteria: results of a randomized study of epoetin alfa versus placebo in anemic lower risk MDS patients Leukemia Research 2017 S23","DOI":"10.1016\/S0145-2126(17)30149-2"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.critrevonc.2003.07.002","article-title":"Systemic chemotherapy in elderly patients with locally advanced and\/or inoperable squamous cell carcinoma of the head and neck: impact of anemia and role of recombinant human erythropoietin","volume":"48","author":"Gebbia","year":"2003","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2002.03774.x","article-title":"Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies","volume":"119","author":"Hedenus","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0194|cit194","doi-asserted-by":"crossref","unstructured":"Heidenreich A Miller K Steiner U Schostak M Prospective clinical phase-II trial on docetaxel and estramustine with or without epoeitin-alpha in patients with metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology 2015","DOI":"10.1200\/jco.2015.33.15_suppl.e16064"},{"issue":"S8","key":"10.1002\/14651858.CD012633.pub2-BIB0195|cit195","first-page":"viii277","article-title":"Randomized, double-blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa (DA) in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy","volume":"19","author":"Katakami","year":"2008","journal-title":"Annals of Oncology"},{"issue":"S1","key":"10.1002\/14651858.CD012633.pub2-BIB0196|cit196","first-page":"58","article-title":"Randomized, double-blind, placebo-controlled phase III study of weekly administration of darbepoetin alfa in anemic patients with lung or gynecologic cancer receiving platinum-containing chemotherapy","volume":"97","author":"Katsumata","year":"2009","journal-title":"Vox Sanguinis"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10147-001-8031-y","article-title":"Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer","volume":"6","author":"Kunikane","year":"2001","journal-title":"International Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012633.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1200\/JCO.2015.63.5649","article-title":"A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy","volume":"34","author":"Leyland-Jones","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.20.01691","article-title":"Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin","volume":"39","author":"List","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0200|cit200","doi-asserted-by":"crossref","unstructured":"List AF Sun Z Verma A Bennett JM McGraw KL Nardelli LA Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo )-refractory, lower risk (LR) non-deletion 5q myelodysplastic syndrome (MDS): results of the E2905 intergroup study-an Blood 2016","DOI":"10.1182\/blood.V128.22.223.223"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"2779-86","DOI":"10.1007\/s00520-017-3690-z","article-title":"Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study","volume":"25","author":"Mafodda","year":"2017","journal-title":"Supportive Care in Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3892\/mco.2015.693","article-title":"Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia","volume":"4","author":"Mountzios","year":"2016","journal-title":"Molecular and Clinical Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0203|cit203","unstructured":"A placebo-controlled study on the effect of epoetin alfa in patients with malignancy receiving chemotherapy. Raritan (NJ): Johnson and Johhnson Pharmaceutical Research and Development Available at www.clinicaltrials.gov\/ct2\/show\/NCT00270166 2005. (date of last access April 13, 2021)"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0204|cit204","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0205|cit205","unstructured":"Background information for Oncologic Drugs Advisory Committee Meeting, Safety of Erythropoietin Receptor Agonists (ERAs) in Patients with Cancer Johnson and Johnson briefing document for FDA\/ODAC hearing May 4, 2004; Gaithersburg, MD,"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2141.1995.tb08374.x","article-title":"Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin","volume":"89","author":"Pangalis","year":"1995","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0207|cit207","doi-asserted-by":"crossref","unstructured":"Gasal E Pan C Tankersley C ARCADE (20090160): a randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) Leukemia Research 2013 S166-S167","DOI":"10.1016\/S0145-2126(13)70367-9"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0208|cit208","unstructured":"Platzbecker U Oliva EN Symeonidis A Delforge M Mayer J Goede JS A multicenter, randomized, double-blind placebocontrolled study of darbepoetin alfa for the treatment of anemic patients with low or intermediate-1 risk myelodysplastic syndrome Hemasphere 2018 717"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0209|cit209","doi-asserted-by":"crossref","unstructured":"Platzbecker U Symeonidis A Oliva E Goede J Delforge M Mayer J A phase 3 randomized placebo (PBO)-controlled double-blind trial of darbepoetin alfa in low or intermediate-1 (INT-1) risk myelodysplastic syndromes (MDS) Haematologica 2017 484","DOI":"10.1016\/S0145-2126(17)30155-8"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0210|cit210","doi-asserted-by":"crossref","unstructured":"Platzbecker U Symeonidis A Oliva E Goede JS Delforge M Mayer J Arcade (20090160): a phase 3 randomized placebo-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) Haematologica 2016 15","DOI":"10.1182\/blood.V128.22.2010.2010"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0211|cit211","doi-asserted-by":"crossref","unstructured":"Platzbecker U Symeonidis A Oliva EN Goede JS Delforge M Mayer J A phase 3 randomized placebo (PBO)-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with low or intermediate-1 (Int-1) risk myelodysplastic syndromes (MDS) Blood 2016","DOI":"10.1016\/S0145-2126(17)30155-8"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0213|cit213","first-page":"1689","article-title":"Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer","volume":"9","author":"Rosen","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0214|cit214","doi-asserted-by":"crossref","unstructured":"Savonije J Van Groeningen C Van Bochove A Pinedo H Giaccone G Early intervention with epoetin-alfa during platinum-based chemotherapy Journal of Clinical Oncology 2004 #8111","DOI":"10.1200\/jco.2004.22.14_suppl.8111"},{"issue":"11","key":"10.1002\/14651858.CD012633.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ejca.2005.03.024","article-title":"Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial","volume":"41","author":"Savonije","year":"2005","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1634\/theoncologist.11-2-197","article-title":"Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data","volume":"11","author":"Savonije","year":"2006","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01696618","article-title":"Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma","volume":"70","author":"Silvestris","year":"1995","journal-title":"Annals of Hematology"},{"issue":"S8","key":"10.1002\/14651858.CD012633.pub2-BIB0218|cit218","first-page":"277","article-title":"Randomized, placebo-controlled phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapy-induced anemia (CIA)","volume":"19","author":"Suzuki","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0219|cit219","doi-asserted-by":"crossref","unstructured":"Tesch H Loibl S Kast K Jackisch C Mobus V Buchen S Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study Annals of Oncology 2019 v65-v66","DOI":"10.1093\/annonc\/mdz240.020"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood.V95.4.1175.004k51_1175_1179","article-title":"Effect of recombinant human erythropoietin combined with granulocyte\/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome","volume":"95","author":"Thompson","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/1471-2407-9-311","article-title":"Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g\/dL versus \u226510 g\/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial","volume":"9","author":"Vansteenkiste","year":"2009","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1537-2995.1996.36296181929.x","article-title":"Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study)","volume":"36","author":"Wurnig","year":"1996","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0223|cit223","doi-asserted-by":"crossref","unstructured":"Anthony L Gabrail N Ghazal H IV iron sucrose for cancer and\/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents https:\/\/www.mdedge.com\/hematology-oncology\/article\/37193\/patient-survivor-care\/iv-iron-sucrose-cancer-and\/or-chemotherapy 2011","DOI":"10.1016\/S1548-5315(12)70022-0"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0224|cit224","unstructured":"A clinical study to assess the absorption and distribution properties of iron isomaltoside 1000 (Monofer\u00c2\u00ae) administered by 500 mg IV bolus injection or 1000 mg intravenous infusion to subjects with non-haematological malignancies associated with chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2011\/12\/002273 2011"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0225|cit225","unstructured":"Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecological) treated with darbepoetin alfa (150 mcg once wee http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2004-002176-42-IT"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0226|cit226","unstructured":"A randomized, multi-center study to assess the effect of Darbepoetin alfa (Aranesp\u00ae) for the treatment of anemia in patients with advanced hormone independent prostate cancer and anaemia - DANCAPepo http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2005-005658-37-DK"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0227|cit227","unstructured":"Prospective controlled clinical trial of metastatic breast cancer treatment with capecitabine\/docetaxel in combination with beta epoetin as compared with sole capecitabine\/docetaxel treatment http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-000137-35-LT"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0228|cit228","unstructured":"Effects of three treatment strategies on anemia and quality of life in patients with solid tumours or lymphoproliferative malignancies http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2006-005965-20-SE"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0229|cit229","unstructured":"A comparative study of low molecular weight IV iron dextran (CosmoFer\u00ae) versus per os iron for the treatment of anaemia in patients with haematological malignancies receiving epoietin treatment http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-005777-57-GR"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0230|cit230","unstructured":"A phase 2, randomised, double-blind, placebo-controlled, dose-finding study of Darbepoetin alfa for the treatment of anemia in paediatric subjects with solid tumours receiving cyclic chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-001721-34-BE"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0231|cit231","unstructured":"A randomized, double-blind, placebo-controlled, multicenter study evaluating epoetin alfa initiated at 40,000 IU every week or 80,000 IU every week versus placebo in subjects with IPSS low- or intermediate-1 risk MDS http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2008-002723-85-IT"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0232|cit232","unstructured":"A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-restricted erythropoiesis receiving chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-015766-56-GR"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0233|cit233","unstructured":"A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies and functional iron deficiency receiving chemotherapy - FER http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2009-015767-14-SE"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0234|cit234","unstructured":"A prospective, randomized, multicenter study to evaluate the impact of Darbepoetin alfa in combination with Ferric(III)-Carboxymaltose in comparison to Darbepoetin alfa and Ferric(III)-Carboxymaltose alone in patients with breast cancer and chemotherapy-i http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-001664-22-AT 2011"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0235|cit235","unstructured":"Blood transfusion reduction with intravenous iron in gynaecological cancer patients receiving chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN01957333"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0236|cit236","unstructured":"Randomised study on haemoglobin response in iron-deficient anaemic patients with solid malignancies receiving epoetin alfa (rHuEPO) in combination with either oral or parental iron supplementation during treatment with non-platinum containing chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN61345286"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0237|cit237","unstructured":"A randomized, double-blind study of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-050013"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0238|cit238","unstructured":"A phase III randomized double-blind placebo-controlled study of epoetin beta for the treatment of chemotherapy-induced anemia in cancer patients http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-080582"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0239|cit239","unstructured":"A novel erythropoiesis stimulating protein (NESP; Darbopoetin Alfa) for the treatment of anemia in lung cancer patients receiving multi-cycle platinum-containing chemotherapy https:\/\/clinicaltrials.gov\/show\/NCT03776032"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0240|cit240","unstructured":"Randomized study on hemoglobin response in iron-deficient anemic patients with solid maglignancies receiving epoetin alfa (rHuEPO) in combination with either oral or parental iron supplementation during treatment with non-platinum containing chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=NTR250"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0241|cit241","unstructured":"Women with breast cancer receiving adjuvant chemotherapy will receive intravenous iron to examine its effect on anaemia and anaemia-related symptoms during chemotherapy and up to 12 months after chemotherapy treatment. https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12620001105932"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"e012231","DOI":"10.1136\/bmjopen-2016-012231","article-title":"Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial","volume":"6","author":"Chen","year":"2016","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0243|cit243","unstructured":"The mechanism of gynecological cancer-related anemia and treatment strategies http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-IPR-16009059"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0244|cit244","unstructured":"The mechanism and treatment strategies of gynecological cancer-related anemia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-IPR-16009508"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0245|cit245","unstructured":"Will intravenous iron reduce blood transfusion in patients undergoing treatment for ovarian cancer http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2019\/05\/019378"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0246|cit246","unstructured":"A study to investigate the efficacy and safety of Injectafer\u00ae (ferric carboxymaltose injection) in anemia due to cancer and chemotherapy http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-002021-11-PL"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0247|cit247","unstructured":"ICaRAS - A feasibility study of intravenous iron therapy for anaemia in palliative cancer care http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-001669-17-GB"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0248|cit248","unstructured":"Intravenous iron for cancer-related anaemia symptoms http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN13370767"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0249|cit249","unstructured":"Multicenter randomized study on the efficacy of intravenous iron injection in cancer patients with anemia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=KCT0004311"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0250|cit250","unstructured":"Erythropoietin and iron supplementation for patients with vhemotherapy-induced anaemia https:\/\/clinicaltrials.gov\/show\/NCT02731378"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0251|cit251","unstructured":"The effectiveness of lactoferrin in the management of treatment-induced anemia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03683810"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0252|cit252","first-page":"74","article-title":"Intravenous ferric carboxymaltose vs. oral iron substitution in patients with metastatic colorectal cancer (mCRC) and iron deficiency anemia: a randomized multicenter treatment optimization study (A Study in Progress Report)","volume":"39","author":"Zur Hausen","year":"2016","journal-title":"Oncology Research and Treatment"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2007.15.4609","article-title":"Should intravenous iron be the standard of care in oncology?","volume":"26","author":"Auerbach","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000091675","article-title":"Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey","volume":"70","author":"Barrett-Lee","year":"2006","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0255|cit255","doi-asserted-by":"crossref","unstructured":"Bellet RE Ghazal H Flam M Drelichman A Gabrail N Woytowitz D A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy Journal of Clinical Oncology 2007 9109","DOI":"10.1200\/jco.2007.25.18_suppl.9109"},{"issue":"8","key":"10.1002\/14651858.CD012633.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0258|cit258","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007303.pub2","article-title":"Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data","author":"Bohlius","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD012633.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS One"},{"issue":"6","key":"10.1002\/14651858.CD012633.pub2-BIB0262|cit262","first-page":"1571","article-title":"On the relative safety of parenteral iron formulations","volume":"19","author":"Chertow","year":"2004","journal-title":"European Dialysis and Transplant Association - European Renal Association"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0263|cit263","first-page":"378","article-title":"Update on adverse drug events associated with parenteral iron","volume":"21","author":"Chertow","year":"2006","journal-title":"European Dialysis and Transplant Association - European Renal Association"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0264|cit264","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.04.002","article-title":"Established search filters may miss studies when identifying randomized controlled trials","volume":"112","author":"Cooper","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0265|cit265","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"issue":"7109","key":"10.1002\/14651858.CD012633.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.beha.2004.09.005","article-title":"Iron requirements in erythropoietin therapy","volume":"18","author":"Eschbach","year":"2005","journal-title":"Best Practice & Research Clinical Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0272-6386(01)80123-2","article-title":"Suspected iron dextran-related adverse drug events in hemodialysis patients","volume":"37","author":"Fletes","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"19","key":"10.1002\/14651858.CD012633.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial","volume":"155","author":"Garton","year":"1995","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","author":"Glanville","year":"2019","journal-title":"Health Information and Libraries Journal"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0273|cit273","unstructured":"GRADEpro Mc Master University 2014"},{"issue":"19","key":"10.1002\/14651858.CD012633.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0276|cit276","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Altman","year":"2011"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0277|cit277","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021) Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0278|cit278","unstructured":"Howlader N Noone AM Krapcho M Garshell J Neyman N Altekruse SF SEER Cancer Statistics Review, 1975-2010. National Cancer Institute. Bethesda, MD http:\/\/seer.cancer.gov\/csr\/1975_2010\/"},{"issue":"21","key":"10.1002\/14651858.CD012633.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.168.21.2377","article-title":"Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer","volume":"168","author":"Khorana","year":"2008","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116 Suppl 7A","author":"Knight","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0282|cit282","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0283|cit283","unstructured":"Li T Higgins JP Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0284|cit284","first-page":"266","article-title":"Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany","volume":"36","author":"Link","year":"2013","journal-title":"Onkologie"},{"issue":"11","key":"10.1002\/14651858.CD012633.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"2 Suppl 8","key":"10.1002\/14651858.CD012633.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0093-7754(01)90206-4","article-title":"Symptomatology of anemia","volume":"28","author":"Ludwig","year":"2001","journal-title":"Seminars in Oncology"},{"issue":"15","key":"10.1002\/14651858.CD012633.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012633.pub2-BIB0288|cit288","first-page":"286","article-title":"Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease","volume":"34","author":"Mamula","year":"2002","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdj038","article-title":"Correlation between anemia and functional\/cognitive capacity in elderly lung cancer patients treated with chemotherapy","volume":"17","author":"Mancuso","year":"2006","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012633.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/jpm.2008.0139","article-title":"Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer","volume":"12","author":"Mercadante","year":"2009","journal-title":"Journal of Palliative Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012633.pub2-BIB0291|cit291","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009624.pub2","article-title":"The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents","author":"Mhaskar","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012633.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0293|cit293","unstructured":"netmeta: Network Meta-Analysis using Frequentist Methods. R package version 1.3-0 R\u00fccker G Krahn U K\u00f6nig J Efthimiou O Schwarzer G http:\/\/CRAN.R-project.org\/package=netmeta 2021"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD012633.pub2-BIB0294|cit294","first-page":"21","article-title":"Epoetin and cognitive function","volume":"20","author":"Nissenson","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"issue":"24","key":"10.1002\/14651858.CD012633.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0296|cit296","first-page":"g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ (Clinical Research ed.)"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0297|cit297","unstructured":"R: A language and environment for statistical computing R Core Team R Foundation for Statistical Computing 2019"},{"issue":"33","key":"10.1002\/14651858.CD012633.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","article-title":"clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"28","author":"Rizzo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012633.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"628","DOI":"10.6004\/jnccn.2012.0064","article-title":"Cancer- and chemotherapy-induced anemia","volume":"10","author":"Rodgers","year":"2012","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"25","key":"10.1002\/14651858.CD012633.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/annonc\/mdq202","article-title":"Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use","volume":"21 Suppl 5","author":"Schrijvers","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0304|cit304","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","author":"Schuenemann","year":"2021"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0305|cit305","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis with R","author":"Schwarzer","year":"2015"},{"issue":"9","key":"10.1002\/14651858.CD012633.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/cncr.11742","article-title":"Cancer-related fatigue: evolving concepts in evaluation and treatment","volume":"98","author":"Stasi","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0307|cit307","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD012633.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"12","key":"10.1002\/14651858.CD012633.pub2-BIB0309|cit309","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003407.pub5","article-title":"Erythropoietin or darbepoetin for patients with cancer","author":"Tonia","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD012633.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2015.15572","article-title":"Comparative risk of anaphylactic reactions associated with intravenous iron products","volume":"314","author":"Wang","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD012633.pub2-BIB0311|cit311","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012633","article-title":"Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis","author":"Weigl","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:46:58Z","timestamp":1716306418000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012633.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":311,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012633.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]}}}